← Leaderboards
Dohun Pyeon
University Of Colorado Denver
$4,808,235
Attributed
$8,125,470
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,125,470 · 4
By mechanism
R01$8,125,470 · 4
Top collaborators
- William Charles Spanos9 shared
- John H Lee1 shared
- Qing-Sheng Mi1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Dedra S Buchwald$63,799,088
- Sana D Karam$9,495,305
- Antonio Jimeno$15,496,689
- Scott A Weed$3,997,953
- Yuwen Zhu$3,496,594
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCellsMouse ModelTumor ProgressionHuman PapillomavirusIn VivoBaseImmunotherapyEpidemicHead And Neck Squamous Cell CarcinomaTumor SuppressionHead And Neck CancerTumor GrowthDisease ProgressionMediatingImmuneNeoplastic CellLinkMalignant Neoplasm Of Cervix UteriCombined Modality TherapyCd8-Positive T-LymphocytesCxcl14 GeneChemokineCessation Of Life
Grant awards (16)
Immune receptor degradation for immune evasion of head and neck cancer$642,488
R01 · FY2025 · DE · contact PI
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer$643,133
R01 · FY2024 · DE · contact PI
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer$656,258
R01 · FY2023 · DE · contact PI
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer$641,281
R01 · FY2022 · DE · contact PI
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer$657,132
R01 · FY2021 · DE · contact PI
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer$626,815
R01 · FY2020 · DE · contact PI
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression$510,770
R01 · FY2020 · DE · contact PI
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression$524,441
R01 · FY2019 · DE · contact PI
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression$668,326
R01 · FY2018 · DE · contact PI
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression$524,976
R01 · FY2017 · DE · contact PI
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression$538,851
R01 · FY2016 · DE · contact PI
Virus-Host Interactions that Modulate Early Steps of Human Papillomavirus Infecti$301,571
R01 · FY2015 · AI · contact PI
Virus-Host Interactions that Modulate Early Steps of Human Papillomavirus Infecti$301,700
R01 · FY2014 · AI · contact PI
Virus-Host Interactions that Modulate Early Steps of Human Papillomavirus Infecti$283,716
R01 · FY2013 · AI · contact PI
Virus-Host Interactions that Modulate Early Steps of Human Papillomavirus Infecti$301,947
R01 · FY2012 · AI · contact PI
Virus-Host Interactions that Modulate Early Steps of Human Papillomavirus Infecti$302,065
R01 · FY2011 · AI · contact PI